Alzheimers Prevention Initiative: A proposal to evaluate presymptomatic treatments as quickly as possible

Biomarkers in Medicine

Volumn 4, Issue 1, 2010, Pages 3-14

  Reiman, Eric M ^a,b,c,d,e   Langbaum, Jessica B S ^a,b,e   Tariot, Pierre N ^a,b,e,f  

^a BANNER ALZHEIMER S INSTITUTE   (United States)

^b BANNER HEALTH   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^e ARIZONA ALZHEIMER S CONSORTIUM   (United States)

^f Alzheimers Disease Cooperative Study ^*  (United States)

Author keywords

Amyloid; Apolipoprotein; Biomarker; Clinical trial; Genetics; MRI; PET; Presenilin; Public policy; Surrogate marker

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; PRESENILIN; TAU PROTEIN; APOLIPOPROTEIN E4; MAPT PROTEIN, HUMAN; NOOTROPIC AGENT;

ALZHEIMER DISEASE; ASYMPTOMATIC DISEASE; BRAIN ATROPHY; CLINICAL RESEARCH; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; DRUG INDUSTRY; EVALUATION RESEARCH; HIGH RISK POPULATION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLICY; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CEREBROSPINAL FLUID; GENETICS; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; HUMANS; MAGNETIC RESONANCE IMAGING; NOOTROPIC AGENTS; POSITRON-EMISSION TOMOGRAPHY; PUBLIC POLICY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAU PROTEINS; UNITED STATES;

EID: 77951669598     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.91     Document Type: Review

References (86)

1. Evans DA, Funkenstein HH, Albert MS et al.: Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 262(18), 2551-2556 (1989).
2. Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88(9), 1337-1342 (1998).
3. Alzheimer's Association: 2009 Alzheimer's disease facts and fgures. Alzheimer's Dement. 5(3), 234-270 (2009).
4. Lautenschlager NT, Cox KL, Flicker L et al.: Effect of physical activity on cognitive function in older adults at risk for alzheimer disease: a randomized trial. JAMA 300(9), 1027-1037 (2008).
5. Wang HX, Karp A, Winblad B, Fratiglioni L: Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project. Am. J. Epidemiol. 155(12), 1081-1087 (2002).
6. Scarmeas N, Luchsinger JA, Schupf N et al.: Physical activity, diet, and risk of Alzheimer disease. JAMA 302(6), 627-637 (2009).
7. Haag MDM, Hofman A, Koudstaal PJ, Stricker BHC, Breteler MMB: Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatr. 80(1), 13-17 (2009).
8. Peila R, White LR, Masaki K, Petrovitch H, Launer LJ: Reducing the risk of dementia: effcacy of long-term treatment of hypertension. Stroke 37(5), 1165-1170 (2006).
9. 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70, 2291-2298 (2008).
10. Zandi PP, Anthony JC, Khachaturian AS et al.: Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neurol. 61(1), 82-88 (2004).
11. Pogacic V, Herrling P: List of drugs in development for neurodegenerative diseases. Update June 2008. Neurodegener. Dis. 6(1-2), 37-86 (2009).
12. Sherrington R, Rogaev EI, Liang Y et al.: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375(6534), 754-760 (1995).
13. Rogaev EI, Sherrington R, Rogaeva EA et al.: Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376(6543), 775-778 (1995).
14. Goate A, Chartier-Harlin MC, Mullan M et al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349(6311), 704-706 (1991). (Pubitemid 21912142)
15. Corder EH, Saunders AM, Strittmatter WJ et al.: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261(5123), 921-923 (1993).
16. 42 ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64(3), 343-349 (2007).
17. 42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69(7), 631-639 (2007).
18. Britschgi M, Olin CE, Johns HT et al.: Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc. Natl Acad. Sci. USA 106(29), 12145-12150 (2009).
19. 40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. J. Nutr. Health Aging 13(3), 205-208 (2009).
20. Britschgi M, Wyss-Coray T: Blood protein signature for the early diagnosis of Alzheimer disease. Arch. Neurol. 66(2), 161-165 (2009).
21. Soares HD, Chen Y, Sabbagh M, Rohrer A, Schrijvers E, Breteler M: Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann. NY Acad. Sci. 1180, 56-67 (2009).
22. Khan TK, Alkon DL: An internally controlled peripheral biomarker for Alzheimer's disease: Erk1 and Erk2 responses to the infammatory signal bradykinin. Proc. Natl Acad. Sci. USA 103(35), 13203-13207 (2006).
23. Langbaum JBS, Chen K, Lee W et al.: Categorical and correlational analyses of baseline fuorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage 45, 1107-1116 (2009).
24. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM: Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am. J. Psychiatry 159(5), 738-745 (2002).
25. Reiman EM: Brain imaging in the presymptomatic detection, tracking and prevention of Alzheimer's disease. Alzheimer's Dement. 5(4), 72 (2009).
26. Reiman EM, Langbaum JBS: Brain imaging in the evaluation of putative Alzheimer's disease slowing, risk-reducing and prevention therapies. In: Imaging the Aging Brain. Jagust WJ, D'Esposito M (Eds). Oxford University Press, Oxford, UK 319-350 (2009).
27. Chen K, Reiman EM, Alexander GE et al.: Correlations between apolipoprotein E e4 gene dose and whole brain atrophy rates. Am. J. Psychiatry 164(6), 916-921 (2007).
28. Jack CR Jr, Lowe VJ, Senjem ML et al.: 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131(3), 665-680 (2008).
29. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 7(2) 129-135 (2008)
30. Small GW, Siddarth P, Burggren AC et al.: Infuence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Arch. Gen. Psychiatry 66(1), 81-87 (2009).
31. Reiman EM, Chen K, Liu X et al.: Fibrillar amyloid-b burden in cognitively normal people at three levels of genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 106(16), 6820-6825 (2009).
32. Ikonomovic MD, Klunk WE, Abrahamson EE et al.: Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131(6), 1630-1645 (2008).
33. Klunk WE, Mathis CA: Amyloid imaging and (what is 'normal'?) aging. In: Imaging the Aging Brain. Jagust WJ, D'Esposito M (Eds). Oxford University Press, Oxford, UK 191-244 (2009).
34. Morris JC, Roe CM, Grant EA et al.: Pittsburgh Compound-B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 66(12), 1469-1475 (2009).
35. Klunk WE, Price JC, Mathis CA et al.: Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci. 27(23), 6174-6184 (2007).
36. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67(3), 446-452 (2006).
37. 18F-AV-45: a PET agent for Ab plaques in the brain. J. Nucl. Med. 50(11), 1887-1894 (2009).
38. 1-42 and increased tau levels in cerebrospinal fuid of patients with Alzheimer disease. JAMA 289(16), 2094-2103 (2003).
39. Mattsson N, Blennow K, Zetterberg H: CSF biomarkers: pinpointing Alzheimer pathogenesis. Ann. NY Acad. Sci. 1180, 28-35 (2009).
40. Reiman EM, Chen K, Alexander GE et al.: Correlations between apolipoprotein E e4 gene dose and brain-imaging measurements of regional hypometabolism. Proc. Natl Acad. Sci. USA 102(23), 8299-8302 (2005).
41. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J: Declining brain activity in cognitively normal apolipoprotein E e4 heterozygotes: a foundation for using positron emission tomography to effciently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98(6), 3334-3339 (2001).
42. Reiman EM, Chen K, Alexander GE et al.: Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl Acad. Sci. USA 101(1), 284-289 (2004).
43. Reiman EM, Caselli RJ, Yun LS et al.: Preclinical evidence of Alzheimer's disease in persons homozygous for the e4 allele for apolipoprotein E. N. Engl. J. Med. 334(12), 752-758 (1996).
44. Reiman EM, Chen K, Caselli RJ et al.: Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions. Neuroimage 40(3), 1214-1221 (2008).
45. Reiman EM, Chen K, Langbaum JB et al.: Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. Neuroimage 49, 169-176 (2010).
46. Mueller SG, Weiner M W, Thal LJ et al.: Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 1(1), 55-66 (2005).
47. Bookheimer SY, Strojwas MH, Cohen MS et al.: Patterns of brain activation in people at risk for Alzheimer's disease. N. Engl. J. Med. 343(7), 450-456 (2000).
48. Small GW, Mazziotta JC, Collins MT et al.: Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273(12), 942-947 (1995).
49. Burggren AC, Zeineh MM, Ekstrom AD et al.: Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers. Neuroimage 41(4), 1177-1183 (2008).
50. Espeseth T, Westlye LT, Fjell AM, Walhovd KB, Rootwelt H, Reinvang I: Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E e4. Neurobiol. Aging 29(3), 329-340 (2008).
51. Filippini N, Macintosh BJ, Hough MG et al.: Distinct patterns of brain activity in young carriers of the APOE-e4 allele. Proc. Natl Acad. Sci. USA 106(17), 7209-7214 (2009).
52. Fleisher AS, Houston WS, Eyler LT et al.: Identifcation of Alzheimer disease risk by functional magnetic resonance imaging. Arch. Neurol. 62(12), 1881-1888 (2005).
53. Jak AJ, Houston WS, Nagel BJ, Corey-Bloom J, Bondi MW: Differential cross-sectional and longitudinal impact of APOE genotype on hippocampal volumes in nondemented older adults. Dement. Geriatr. Cogn. Disord. 23(6), 382-389 (2007).
54. Johnson SC, Schmitz TW, Trivedi MA et al.: The infuence of Alzheimer disease family history and apolipoprotein E e4 on mesial temporal lobe activation. J. Neurosci. 26(22), 6069-6076 (2006).
55. Lind J, Persson J, Ingvar M et al.: Reduced functional brain activity response in cognitively intact apolipoprotein E e4 carriers. Brain 129(Pt 5), 1240-1248 (2006).
56. Moffat SD, Szekely CA, Zonderman AB, Kabani NJ, Resnick SM: Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype. Neurology 55(1), 134-136 (2000).
57. Mosconi L, De SS, Brys M et al.: Hypometabolism and altered cerebrospinal fuid markers in normal apolipoprotein E e4 carriers with subjective memory complaints. Biol. Psychiatry 63(6), 609-618 (2008).
58. Shaw P, Lerch JP, Pruessner JC et al.: Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurol. 6(6), 494-500 (2007).
59. Godbolt AK, Cipolotti L, Anderson VM et al.: A decade of pre-diagnostic assessment in a case of familial Alzheimer's disease: tracking progression from asymptomatic to MCI and dementia. Neurocase 11(1), 56-64 (2005).
60. Godbolt AK, Waldman AD, MacManus DG et al.: MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 66(5), 718-722 (2006).
61. Ridha BH, Barnes J, Bartlett JW et al.: Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol. 5(10), 828-834 (2006).
62. Schott JM, Fox NC, Frost C et al.: Assessing the onset of structural change in familial Alzheimer's disease. Ann. Neurol. 53(2), 181-188 (2003).
63. Fox NC, Warrington EK, Stevens JM, Rossor MN: Atrophy of the hippocampal formation in early familial Alzheimer's disease. A longitudinal MRI study of at-risk members of a family with an amyloid precursor protein 717Val-Gly mutation. Ann. NY Acad. Sci. 777, 226-232 (1996).
64. Scholl M, Almkvist O, Axelman K et al.: Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol. Aging (2009) (In Press).
65. Mosconi L, Sorbi S, de Leon MJ et al.: Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J. Nucl. Med. 47(11), 1778-1786 (2006).
66. Kennedy AM, Frackowiak RS, Newman SK et al.: Defcits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci. Lett. 186(1), 17-20 (1995).
67. Kennedy AM, Rossor MN, Frackowiak RS: Positron emission tomography in familial Alzheimer disease. Alzheimer Dis. Assoc. Disord. 9(1), 17-20 (1995).
68. Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN: Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet 358(9277), 201-205 (2001).
69. Cutler NR, Haxby JV, Duara R et al.: Brain metabolism as measured with positron emission tomography: serial assessment in a patient with familial Alzheimer's disease. Neurology 35(11), 1556-1561 (1985).
70. Ginestroni A, Battaglini M, Della NR et al.: Early structural changes in individuals at risk of familial Alzheimer's disease: a volumetry and magnetization transfer MR imaging study. J. Neurol. 256(6), 925-932 (2009).
71. Johnson KA, Lopera F, Jones K et al.: Presenilin-1-associated abnormalities in regional cerebral perfusion. Neurology 56(11), 1545-1551 (2001).
72. 1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE e4 allele. Biol. Psychiatry 56(9), 670-676 (2004).
73. Glodzik-Sobanska L, Pirraglia E, Brys M et al.: The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol. Aging 30(5), 672-681 (2009).
74. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5(3), 228-234 (2006).
75. ADAPT Research Group: Cognitive function over time in the Alzheimer's Disease Anti-infammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol. 65(7), 896-905 (2008).
76. DeKosky ST, Fitzpatrick A, Ives DG et al.: The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp. Clin. Trials 27(3), 238-253 (2006).
77. Shumaker SA, Legault C, Rapp SR et al.: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 289(20), 2651-2662 (2003).
78. Shumaker SA, Legault C, Kuller L et al.: Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 291(24), 2947-2958 (2004).
79. Fleming TR, DeMets DL: Surrogate end points in clinical trials: are we being misled? Ann. Intern. Med. 125(7), 605-613 (1996).
80. Katz R: Biomarkers and surrogate markers: an FDA perspective. NeuroRx 1(2), 189-195 (2004).
81. Fox NC, Black RS, Gilman S et al.: Effects of Ab immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64(9), 1563-1572 (2005).
82. Khachaturian ZS, Petersen RC, Gauthier S et al.: A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimer's Dement. 4(3), 156-163 (2008).
83. Khachaturian ZS, Khachaturian AS: Prevent Alzheimer's disease by 2020: a national strategic goal. Alzheimer's Dement. 5(2), 81-84 (2009).
84. Roses AD: Commentary on "A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium." An impending prevention clinical trial for Alzheimer's disease: roadmaps and realities. Alzheimer's Dement. 4(3), 164-166 (2008).
85. Siemers ER, Paul SM: Commentary on "A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium". Alzheimer's Dement. 4(3), 171-173 (2008).
86. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43(11), 2412-2414 (1993).